Cassava Sciences, Inc. (SAVA) Stock
SAVA Key Statistics
About Cassava Sciences, Inc.
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.
CEO: Richard Jon Barry. Company website
SAVA — Frequently Asked Questions
What is the SAVA stock price today?
Cassava Sciences, Inc. (SAVA) trades at $1.32, down 36.84% on the day, as of Oct 23, 2026 00:43 UTC.
What is Cassava Sciences, Inc.'s market cap?
Cassava Sciences, Inc. has a market capitalisation of $63.77M, calculated from the live SAVA share price and shares outstanding.
What is the P/E ratio of SAVA?
SAVA has no meaningful price-to-earnings ratio: Cassava Sciences, Inc. lost $0.87 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Cassava Sciences, Inc. make?
Cassava Sciences, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for SAVA?
SAVA has traded between $0.86 and $4.69 over the past 52 weeks, and the last price is 71.9% below that high.
Is Cassava Sciences, Inc. profitable?
Yes. Cassava Sciences, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for SAVA?
Wall Street analysts rate SAVA Buy.
What sector is Cassava Sciences, Inc. in?
Cassava Sciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Cassava Sciences, Inc.?
Richard Jon Barry is the chief executive of Cassava Sciences, Inc., which employs 30 people.
Where can I track SAVA in real time?
QFI Terminal shows SAVA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See SAVA live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SAVA in Terminal See plans